Delving into the Latest Updates on Elcatonin with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Elcatonin (JP17/INN)

+ [7]

Target

CALCR

Mechanism

CALCR inhibitors(Calcitonin receptor inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication

Familial Paget's Disease of BoneHypercalcemiaOsteoporosis

Inactive Indication

HemiplegiaStroke

Originator Organization

Asahi Kasei Corp.

Active Organization

Asahi Kasei Corp.

Shandong Luye Pharmaceutical Co., Ltd.

Inactive Organization

Asahi Kasei Pharma Corp.

Drug Highest PhaseApproved

First Approval Date

JP (15 Jun 1982),

Osteoporosis

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC148H244N42O47

InChIKeyDDPFHDCZUJFNAT-PZPWKVFESA-N

CAS Registry60731-46-6

Gene Sequence

Sequence Code 1000323

Source: *****

INTRODUCTION AND IMPORTANCEAlthough corticosteroids are effective for bronchial asthma, they are associated with various side effects, such as osteonecrosis of the femoral head and tibial condyle and osteoporosis. Here, we report a patient who was on corticosteroids for a long period of time due to severe asthma, which was thought to have led to lunate osteonecrosis of both wrist joints. Calcitonin (elcatonin), an osteoporosis drug, was administered to the wrist joint.CASE PRESENTATIONAllergy to anesthetics and various non-steroidal anti-inflammatory drugs (NSAIDs) made surgical treatment not possible and pain control difficult. In addition, pain in the wrist joint interfered with activities of daily living (ADLs). When calcitonin was administered intra-articularly into the wrist joint, the pain in the wrist joint was relieved and ADLs were improved. However, the pain-suppressing effect lasted only 1 week, and pain returned to the original state by the second week after treatment. Repeated injections were necessary every 2 weeks.CLINICAL DISCUSSIONThis is the first report of the effectiveness of intra-articular calcitonin in a patient with osteonecrosis of the lunate. This treatment may be applicable to patients with allergies to anesthesia and NSAIDs.CONCLUSIONIn the present case, calcitonin administered intra-articularly to the wrist appeared to be effective in pain control for steroid-induced lunate osteonecrosis.

01 Jan 2023·BioMed Research International

Retracted: Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Author: International, BioMed Research

[This retracts the article DOI: 10.1155/2022/1213278.].

07 Sep 2022·BioMed Research International

Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Article

Author: Wang, Baohui ; Liu, Na ; Han, Xiuwei ; Shi, Da ; Wang, Bo ; Sun, Yindi

Objective. This research aims to investigate and analyze the impact of alendronate sodium (ALN) plus elcatonin (EC) in treating postoperative bone pain (BP) in patients with osteoporotic fractures (OPFs). Methods. One hundred and thirty-eight cases of OPFs admitted between July 2018 and July 2021 were selected, of which 68 cases receiving ALN were set as the control group and 70 cases receiving ALN plus EC were set as the research group. Intercomparisons were performed in terms of BP, curative effect, complication rate, and serum bone metabolism indexes such as bone Gla protein (BGP), parathyroid hormone (PTH), and bone alkaline phosphatase (BALP). Results. Better postoperative BP relief, higher overall response rate, and lower complication rate were identified in the research group versus the control group. On the other hand, the research group presented with increased BGP and BALP after treatment, higher than those in the control group, while the posttreament PTH decreased obviously and was lower versus the control group.Conclusions. For OPF patients, ALN plus EC contributes to significantly reduced postoperative BP, improved clinical efficacy, higher treatment safety, and better bone metabolism, which has high clinical application value.

100 Deals associated with Elcatonin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03287	Elcatonin	H05BA04	DB13742

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Familial Paget's Disease of Bone	JP	Asahi Kasei Corp.	07 Feb 2006
Hypercalcemia	CN	Shandong Luye Pharmaceutical Co., Ltd.	01 Jan 2000
Osteoporosis	JP	Asahi Kasei Corp.	15 Jun 1982

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemiplegia	Phase 2	JP	Asahi Kasei Pharma Corp.	01 Jul 2012
Stroke	Phase 2	JP	Asahi Kasei Pharma Corp.	01 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2018	Not Applicable	Osteoporosis	-	Elcatonin	rejzqmhomx(guvumcjqcs) = bczdpquomk mrewsurwqa (tlsrrotzov )	Negative	23 Oct 2018
				Elcatonin	rejzqmhomx(guvumcjqcs) = dqhdlwndwy mrewsurwqa (tlsrrotzov )